Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened

Xilio Therapeutics, Inc. (NASDAQ:XLO) fell 12.3% during trading on Friday . The stock traded as low as $0.92 and last traded at $0.93. 3,402,375 shares changed hands during trading, a decline of 48% from the average session volume of 6,502,162 shares. The stock had previously closed at $1.06.

Analyst Ratings Changes

Separately, Raymond James decreased their price objective on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

Xilio Therapeutics Price Performance

The company has a fifty day moving average price of $0.98 and a 200 day moving average price of $0.94. The stock has a market cap of $40.88 million, a P/E ratio of -0.54 and a beta of -0.30.

Institutional Investors Weigh In On Xilio Therapeutics

Several institutional investors have recently bought and sold shares of XLO. Geode Capital Management LLC grew its holdings in Xilio Therapeutics by 85.0% during the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after buying an additional 155,337 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Xilio Therapeutics during the fourth quarter worth $48,000. Takeda Pharmaceutical Co. Ltd. bought a new stake in Xilio Therapeutics during the fourth quarter worth $1,416,000. Renaissance Technologies LLC grew its holdings in Xilio Therapeutics by 11.4% during the fourth quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock worth $283,000 after buying an additional 30,317 shares in the last quarter. Finally, Gilead Sciences Inc. bought a new stake in Xilio Therapeutics during the fourth quarter worth $8,696,000. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.